399441 生物医药
已收盘 01-26 15:00:00
资讯
新帖
简况
成大生物最新公告：拟与控股股东等共同设立生物医药产业投资基金
证券之星 · 18:38
成大生物最新公告：拟与控股股东等共同设立生物医药产业投资基金
1月26日智飞生物涨14.87%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 15:50
1月26日智飞生物涨14.87%，招商国证生物医药指数(LOF)C基金重仓该股
港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%
老虎资讯综合 · 01-23
港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%
近五成生物医药公司业绩预喜 多家CXO企业表现亮眼
南方财经网 · 01-23
近五成生物医药公司业绩预喜 多家CXO企业表现亮眼
港股异动 | 维亚生物(01873)盘中涨近7% 维亚生物创新研讨会呈现生物医药研发新路径
智通财经 · 01-22
港股异动 | 维亚生物(01873)盘中涨近7% 维亚生物创新研讨会呈现生物医药研发新路径
招商基金侯昊旗下招商国证生物医药年报最新持仓，重仓药明康德
证券之星 · 01-21
招商基金侯昊旗下招商国证生物医药年报最新持仓，重仓药明康德
1月19日智飞生物跌7.19%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 01-19
1月19日智飞生物跌7.19%，招商国证生物医药指数(LOF)C基金重仓该股
【新股IPO】成都赜灵生物医药科技股份有限公司向港交所主板提交上市申请
金吾财讯 · 01-13
【新股IPO】成都赜灵生物医药科技股份有限公司向港交所主板提交上市申请
中赋科技：择机投资生物医药领域优质项目
证券之星 · 01-13
中赋科技：择机投资生物医药领域优质项目
*ST景峰最新公告：聚焦心血管领域产品拓展销售渠道培育生物医药第二增长曲线
证券之星 · 01-12
*ST景峰最新公告：聚焦心血管领域产品拓展销售渠道培育生物医药第二增长曲线
浙商证券：AI应用多点开花 看好AI+生物医药投资机会
智通财经 · 01-12
浙商证券：AI应用多点开花 看好AI+生物医药投资机会
1月12日长春高新涨5.79%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 01-12
1月12日长春高新涨5.79%，招商国证生物医药指数(LOF)C基金重仓该股
黄埔天河两区开年发力，抢占生物医药新赛道
21世纪经济报道 · 01-09
黄埔天河两区开年发力，抢占生物医药新赛道
前传奇生物副总裁潘琦加盟水木分子，出任生物医药首席科学家
新浪科技 · 01-09
前传奇生物副总裁潘琦加盟水木分子，出任生物医药首席科学家
东富龙：坚守专业技术服务于生物医药
证券之星 · 01-08
东富龙：坚守专业技术服务于生物医药
英硅智能与施维雅达成总额8.88亿美元合作：2026生物医药首例BD交易，2025年BD交易总额超1300亿美元创历史新高
蓝鲸财经 · 01-05
英硅智能与施维雅达成总额8.88亿美元合作：2026生物医药首例BD交易，2025年BD交易总额超1300亿美元创历史新高
*ST宁科（600165）股东湖南新合新生物医药有限公司质押1.78亿股，占总股本11.03%
证券之星 · 01-01
*ST宁科（600165）股东湖南新合新生物医药有限公司质押1.78亿股，占总股本11.03%
【新股IPO】景泽生物医药(合肥)股份有限公司向港交所主板提交上市申请
金吾财讯 · 2025-12-31
【新股IPO】景泽生物医药(合肥)股份有限公司向港交所主板提交上市申请
位于大兴生物医药基地，首都医科大学新校区首栋钢结构建筑封顶
新京报 · 2025-12-29
位于大兴生物医药基地，首都医科大学新校区首栋钢结构建筑封顶
微光股份：离心风机EC风机终端可应用于半导体生物医药
证券之星 · 2025-12-29
微光股份：离心风机EC风机终端可应用于半导体生物医药
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"399441","market":"SZ","secType":"STK","nameCN":"生物医药","latestPrice":2294.22,"timestamp":1769411034000,"preClose":2257.38,"halted":0,"volume":1055453932,"delay":0,"changeRate":0.0163,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":36.84,"latestTime":"01-26 15:00:00","open":2266.85,"high":2304.48,"low":2240.71,"amount":25534000000,"amplitude":0.0283,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769477400000},"marketStatusCode":5,"adr":0,"adjPreClose":2257.38,"symbolType":"index","openAndCloseTimeList":[[1769391000000,1769398200000],[1769403600000,1769410800000]],"highLimit":0,"lowLimit":0,"ibTradeSell":false,"ibTradeBuySell":false,"isCdr":false,"pbRate":0,"marketValue":0,"turnoverRate":0,"status":0,"floatMarketCap":0},"requestUrl":"/m/hq/s/399441","defaultTab":"news","newsList":[{"id":"2606211320","title":"成大生物最新公告：拟与控股股东等共同设立生物医药产业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2606211320","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606211320?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:38","pubTimestamp":1769423898,"startTime":"0","endTime":"0","summary":"成大生物(688739.SH)公告称，公司拟与控股股东辽宁成大及其全资子公司成大沿海、公司全资子公司深圳成大生物共同投资设立成大生物医药产业投资基金（有限合伙），基金总规模不超过100,000万元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600026057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239","399441","161726"],"gpt_icon":0},{"id":"2606971562","title":"1月26日智飞生物涨14.87%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606971562","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606971562?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:50","pubTimestamp":1769413858,"startTime":"0","endTime":"0","summary":"证券之星消息，1月26日智飞生物涨14.87%，收盘报19.85元，换手率8.77%，成交量124.06万手，成交额23.64亿元。重仓智飞生物的前十大公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共13家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为14.39亿元，最新净值0.4131，较上一交易日上涨1.27%，近一年上涨15.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU1328615791.USD","300122","BK0196","LU1064130708.USD","399441","LU2580892789.USD","BK0239","BK0188","LU2580892862.HKD","161726","BK0046","LU2148510915.USD","BK0077"],"gpt_icon":0},{"id":"1199361007","title":"港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199361007","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199361007?lang=zh_cn&edition=full","pubTime":"2026-01-23 09:54","pubTimestamp":1769133269,"startTime":"0","endTime":"0","summary":"1月23日，港股生物医药股普涨，$康方生物(09926)$涨超5%，$荣昌生物(09995)$涨超3%，$泰格医药(03347)$、$君实生物(01877)$、$百济神州(06160)$、$药明合联(02268)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"de741e781d04bd03f8ca00d2fa57ffc6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IE00B5MMRT66.SGD","LU0348767384.USD","IE00B543WZ88.USD","LU1969619763.USD","LU2399975544.HKD","BK1610","LU0348783233.USD","LU1064131003.USD","LU1794554557.SGD","BK4585","LU0417516738.SGD","IE00BPRC5H50.USD","LU2328871848.SGD","BK1574","LU2148510915.USD","09995","LU2778985437.USD","09926","LU0348735423.USD","399441","BK1583","LU0348825331.USD","LU2488822045.USD","BK4588","BK0239","LU0348784397.USD","LU0417516571.SGD","LABU","688331","LU0417516902.SGD","LU1720050803.USD","LU2476274720.SGD","LU2476274308.USD","161726","LU0348766576.USD","LU0540923850.HKD","LU0561508036.HKD","LU0348827113.USD","LU1961090484.USD","LU1064130708.USD","02800","LU0634319403.HKD"],"gpt_icon":0},{"id":"2605449493","title":"近五成生物医药公司业绩预喜 多家CXO企业表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2605449493","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605449493?lang=zh_cn&edition=full","pubTime":"2026-01-23 08:24","pubTimestamp":1769127883,"startTime":"0","endTime":"0","summary":"南方财经1月23日电，据中证报，截至1月22日，按照申万一级行业划分，已有逾50家生物医药企业披露2025年业绩预告，27家预喜，预喜比例近五成。值得关注的是，多家CXO（医药外包服务，包括CDMO和CRO）公司业绩表现亮眼。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601233628152649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["399441","161726","CXO","BK4585","BK4588","LABU"],"gpt_icon":0},{"id":"2605450959","title":"港股异动 | 维亚生物(01873)盘中涨近7% 维亚生物创新研讨会呈现生物医药研发新路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2605450959","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605450959?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:03","pubTimestamp":1769065433,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维亚生物盘中涨近7%，截至发稿，涨4.21%，报1.98港元，成交额1604.8万港元。消息面上，据维亚生物公众号，1月13日，维亚生物在第44届J.P. Morgan Healthcare Conference期间举办创新研讨会，吸引众多专业人士交流。研讨会聚焦人工智能与新药物类型前沿进展，维亚生物就AI赋能多肽药物研发全流程实验设计以及AI赋能多肽CRDMO平台展开分享，集中体现了人工智能如何在研发与产业化关键环节的加速落地，成为本次会议的重要看点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1610","BK1141","BK1576","BK4585","BK4588","01873","LABU","161726","399441"],"gpt_icon":0},{"id":"2605141127","title":"招商基金侯昊旗下招商国证生物医药年报最新持仓，重仓药明康德","url":"https://stock-news.laohu8.com/highlight/detail?id=2605141127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605141127?lang=zh_cn&edition=full","pubTime":"2026-01-21 05:29","pubTimestamp":1768944545,"startTime":"0","endTime":"0","summary":"证券之星消息，1月21日招商基金旗下侯昊 许荣漫管理的招商国证生物医药指数基金(LOF)公布年报，近1年净值增长率16.19%。其中药明康德持仓占比9.84%，为该基金第一大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100003045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","LU1997244956.HKD","LU0320764599.SGD","LU1979443071.USD","LU0708995583.HKD","LU2242644610.SGD","161726","LU2495084118.USD","BK1576","LU0456842615.SGD","399441","LU2045819591.USD","BK1141","BK0216","LU1997245177.USD","603259","LU1997245094.SGD","LU2328871848.SGD","LU2488822045.USD","BK1583","LU1808992512.USD","LU1046422090.SGD","LU1934453819.USD","LU2125910500.SGD","02359","LU0052750758.USD"],"gpt_icon":0},{"id":"2604185464","title":"1月19日智飞生物跌7.19%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604185464","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604185464?lang=zh_cn&edition=full","pubTime":"2026-01-19 15:41","pubTimestamp":1768808495,"startTime":"0","endTime":"0","summary":"证券之星消息，1月19日智飞生物跌7.19%创60日新低，收盘报17.56元，换手率4.37%，成交量61.86万手，成交额11.02亿元。重仓智飞生物的前十大公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共15家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4203，较上一交易日下跌0.97%，近一年上涨17.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900014545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","161726","LU1064131003.USD","LU2580892789.USD","BK0077","300122","399441","BK0188","BK0239","LU2148510915.USD","LU1064130708.USD","LU1328615791.USD","LU2580892862.HKD","BK0196"],"gpt_icon":0},{"id":"2603635495","title":"【新股IPO】成都赜灵生物医药科技股份有限公司向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2603635495","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603635495?lang=zh_cn&edition=full","pubTime":"2026-01-13 23:43","pubTimestamp":1768318982,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所1月13日披露，成都赜灵生物医药科技股份有限公司向港交所主板提交上市申请，杰富瑞、中金公司为其联席保荐人。公司已经建立由八项专有资产组成的强大且多元化的管线，涵盖临床及临床前阶段。其中，两种候选药物已进入3期注册性临床试验阶段，包括用于治疗骨髓纤维化的FM及用于治疗复发╱难治弥漫性大B细胞淋巴瘤的PM。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973157","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161726","399441","HEXmain"],"gpt_icon":0},{"id":"2603503533","title":"中赋科技：择机投资生物医药领域优质项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2603503533","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603503533?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:06","pubTimestamp":1768287980,"startTime":"0","endTime":"0","summary":"证券之星消息，中赋科技(300692)01月13日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司接下来的业务会沿着ai医疗，生物医药，多模态Ai的方向发展吗中赋科技回复：尊敬的投资者您好，公司会从提升上市公司持续盈利能力、优化资产质量的长远目标出发，择机投资生物医药领域优质项目，培育新的利润增长点。具体业务情况请以公司披露的定期报告及临时公告为准。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300019582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161726","399441"],"gpt_icon":0},{"id":"2602113495","title":"*ST景峰最新公告：聚焦心血管领域产品拓展销售渠道培育生物医药第二增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2602113495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602113495?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:30","pubTimestamp":1768217404,"startTime":"0","endTime":"0","summary":"*ST景峰公告称，景峰医药的经营方案包括优化存量和培育增量两部分。在优化存量方面，公司将聚焦心血管领域产品，提升营销能力，并创新创研新产品。具体举措包括成立心血管销售部，优化产品管线，拓展销售渠道，以及建立和壮大零售队伍。在培育增量方面，公司将重点培育生物医药作为第二增长曲线，依托常德市的政策支持和石药控股集团的研发实力，引入优质合成生物学项目，并设立专项产业基金进行项目孵化与引入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200031348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161726","000908","399441","BK0239","BK0056"],"gpt_icon":0},{"id":"2602952594","title":"浙商证券：AI应用多点开花 看好AI+生物医药投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2602952594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602952594?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:53","pubTimestamp":1768204413,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，浙商证券发布研报称，AI医疗应用在国家战略与市场需求的共振下已迈入商业化落地的快速阶段。该行认为AI制药核心价值在于大幅提升药物早研效率，看好国内多家AI制药平台服务能力全球领先。AI制药的高需求将带来较大的落地验证实验及合作需求，建议关注已与AI制药平台有战略合作的传统CRO公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601878","161726","399441","BK0276"],"gpt_icon":0},{"id":"2602948185","title":"1月12日长春高新涨5.79%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602948185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602948185?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:41","pubTimestamp":1768203693,"startTime":"0","endTime":"0","summary":"证券之星消息，1月12日长春高新涨5.79%，收盘报103.57元，换手率4.24%，成交量16.94万手，成交额17.25亿元。重仓长春高新的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共83家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4219，较上一交易日上涨1.54%，近一年上涨18.54%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200015175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0075","399441","161726","BK0057","000661","BK0046","BK0028"],"gpt_icon":0},{"id":"2602775203","title":"黄埔天河两区开年发力，抢占生物医药新赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2602775203","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602775203?lang=zh_cn&edition=full","pubTime":"2026-01-09 23:08","pubTimestamp":1767971300,"startTime":"0","endTime":"0","summary":"在2026年开年伊始，广州市黄埔区和天河区，都将目光瞄准到生物医药领域。1月5日，黄埔区举办了一场媒体调研行广州国际生物岛专场活动。紧接着，一天之后，6日，在广州国际金融城召开了天河区新年第一场产业对接活动，活动主题也聚焦生物医药。“这款氘泊替诺雷（AR882）不仅能降尿酸，更能直接溶解痛风石，填补了全球口服小分子药物在该领域的治疗空白。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601093614610219.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601093614610219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["161726","399441"],"gpt_icon":0},{"id":"2602031467","title":"前传奇生物副总裁潘琦加盟水木分子，出任生物医药首席科学家","url":"https://stock-news.laohu8.com/highlight/detail?id=2602031467","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602031467?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:39","pubTimestamp":1767919140,"startTime":"0","endTime":"0","summary":"新浪科技讯 1月9日上午消息，新浪科技独家获悉，原传奇生物研发副总裁潘琦已加入清华大学智能产业院 孵化成立的AI生物医药企业“水木分子”，将出任生物医药首席科学家全面负责公司生物医药与ChatDD科研战略、研发体系建设、AI 药物管线推进及全球合作布局等工作。 据知情人士对新浪科技透露，加入水木分子前，潘琦近期曾任职于美国知名AI肿瘤生物技术公司Pathos，任癌症生物学高级副总裁。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tob/2026-01-09/doc-inhfsfzv3104115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["161726","BK4505","BK4585","BK4588","BK4139","399441","LEGN"],"gpt_icon":0},{"id":"2601833831","title":"东富龙：坚守专业技术服务于生物医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2601833831","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601833831?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:45","pubTimestamp":1767833113,"startTime":"0","endTime":"0","summary":"证券之星消息，东富龙(300171)01月08日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的企业文化是什么？可以详细的解说一下吗？谢谢东富龙回复：您好，公司及全体员工秉承“天道酬勤、诚信、敬业、创新、学习”的价值观，坚守专业技术服务于生物医药，致力于成为智慧药厂的交付者。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800006160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161726","399441","BK0251","300171"],"gpt_icon":0},{"id":"2601083830","title":"英硅智能与施维雅达成总额8.88亿美元合作：2026生物医药首例BD交易，2025年BD交易总额超1300亿美元创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2601083830","media":"蓝鲸财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601083830?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:19","pubTimestamp":1767626351,"startTime":"0","endTime":"0","summary":"2026年，生物医药首例BD交易发生在AI制药领域，根据港股上市公司英硅智能公告显示，其与施维雅达成为期多年的研发合作，协议涉及总金额高达8.88亿美元，合作将充分利用英硅智能自主研发的人工智能平台Pharma.AI，聚焦于抗肿瘤领域具有挑战性的靶点，识别并开发全新的治疗药物。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"553701c0628857e3aa8ad30c26408e63","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1767584751804377677","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["161726","399441"],"gpt_icon":0},{"id":"2600070314","title":"*ST宁科（600165）股东湖南新合新生物医药有限公司质押1.78亿股，占总股本11.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600070314","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600070314?lang=zh_cn&edition=full","pubTime":"2026-01-01 00:23","pubTimestamp":1767198199,"startTime":"0","endTime":"0","summary":"证券之星消息，*ST宁科1月1日公开信息显示，股东湖南新合新生物医药有限公司向上海浦东发展银行股份有限公司长沙分行合计质押1.78亿股，占总股本11.03%。质押详情见下表：截止本公告日，股东湖南新合新生物医药有限公司已累计质押股份1.78亿股，占其持股总数的49.9%，股东上海中能企业发展(集团)有限公司已累计质押股份2.0亿股，占其持股总数的100.0%。*ST宁科主营业务：长链二元酸及煤质活性炭的生产销售业务及贸易业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010100000165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","600165","BK0077","BK0042","161726","399441","BK0070","BK0174"],"gpt_icon":0},{"id":"2595770234","title":"【新股IPO】景泽生物医药(合肥)股份有限公司向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2595770234","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595770234?lang=zh_cn&edition=full","pubTime":"2025-12-31 23:25","pubTimestamp":1767194712,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所12月31日披露，景泽生物医药 股份有限公司向港交所主板提交上市申请，中金公司、国元国际为其联席保荐人。公司是一家历史可追溯至2014年，专注于辅助生殖药物和眼科药物两大赛道的生物制药公司。财务方面，于2023年-2024年度及2025年截至6月30日止六个月，研发开支分别为1.22亿元、1.33亿元及82.9万元；对应同期，年内亏损及全面亏损总额分别为2.46亿元、2.43亿元及1.28亿元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NzQzNDA1NDU2OTQ1Mw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NzQzNDA1NDU2OTQ1Mw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972433","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEXmain","161726","399441"],"gpt_icon":0},{"id":"2595738783","title":"位于大兴生物医药基地，首都医科大学新校区首栋钢结构建筑封顶","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738783","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595738783?lang=zh_cn&edition=full","pubTime":"2025-12-29 20:50","pubTimestamp":1767012600,"startTime":"0","endTime":"0","summary":"新京报讯 12月29日，随着最后一根钢梁被稳稳吊起，首都医科大学新校区（校本部）项目首栋钢结构顺利封顶。首都医科大学新校区项目位于大兴新城生物医药基地北拓区东北角，步入施工现场，一栋栋钢结构建筑拔地而起。12月29日，首都医科大学新校区（校本部）项目部，封顶仪式现场。记者了解到，首都医科大学新校区（校本部）计划在2028年投用。","market":"us","thumbnail":"https://media.bjnews.com.cn/image/2025/12/29/5669809235433696363.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/image/2025/12/29/5669809235433696363.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1767012029129345.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1767012029129345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["161726","399441"],"gpt_icon":0},{"id":"2595868785","title":"微光股份：离心风机EC风机终端可应用于半导体生物医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2595868785","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595868785?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:03","pubTimestamp":1766998997,"startTime":"0","endTime":"0","summary":"证券之星消息，微光股份(002801)12月29日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，我看到贵公司回答说离心风机、EC风机已应用于洁净室行业，目前销售占比公司总营收比重不高。这里提到的洁净室是为半导体行业提供有关的洁净室服务吗？微光股份回复：你好，公司离心风机、EC 风机配套于相关洁净室设备，终端可应用于半导体、生物医药等多个领域，受产业链分工及产品最终使用场景多样性影响，无法精准统计应用于半导体领域的具体营收情况。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900021867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002801","161726","BK0224","399441","159582"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769433241938,"stockEarnings":[{"period":"1week","weight":-0.0179},{"period":"1month","weight":0.0374},{"period":"3month","weight":-0.0452},{"period":"6month","weight":-0.0323},{"period":"1year","weight":0.1556},{"period":"ytd","weight":0.0519}],"compareEarnings":[{"period":"1week","weight":0.0083},{"period":"1month","weight":0.0495},{"period":"3month","weight":0.047},{"period":"6month","weight":0.151},{"period":"1year","weight":0.2805},{"period":"ytd","weight":0.0422}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物医药(399441)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物医药(399441)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物医药,399441,生物医药股票,生物医药股票老虎,生物医药股票老虎国际,生物医药行情,生物医药股票行情,生物医药股价,生物医药股市,生物医药股票价格,生物医药股票交易,生物医药股票购买,生物医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物医药(399441)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物医药(399441)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}